Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Bayer Partner on Cancer Companion Dx

NEW YORK (GenomeWeb News) – Qiagen today said that it will collaborate with Bayer HealthCare on developing companion diagnostics for Bayer drugs with an initial focus on those that target solid tumors.

The companion diagnostic tests will run on Qiagen's QIA symphony automated instruments. In addition, the partners said that they will collaborate on developing technologies for patient profiling, which may result on research-use-only products for exploratory and translational medicine, said Qiagen.

"The first collaborations for Bayer HealthCare and Qiagen include companion diagnostics based on the identification of patients who may respond to therapies in clinically unmet disease classifications," Helge Lubenow, SVP of the molecular diagnostics business area and member of the executive committee of Qiagen, said in a statement. "Our agreement also lays the groundwork for a strong partnership in creating future companion diagnostics both inside and outside of oncology."

Financial and other terms of the alliance were not disclosed.

Qiagen said that it has more than 15 companion diagnostic collaborations ongoing with pharmaceutical and biotech companies.

In early July the US Food and Drug Administration cleared for marketing Qiagen's therascreen KRAS RGQ PCR Kit to be sold as a companion diagnostic test for Erbitux (cetuximab), a drug used for treating colorectal cancer.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.